Search Results - "Deneer, V H"

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium by van der Wouden, CH, Cambon‐Thomsen, A, Cecchin, E, Cheung, KC, Dávila‐Fajardo, CL, Deneer, VH, Dolžan, V, Ingelman‐Sundberg, M, Jönsson, S, Karlsson, MO, Kriek, M, Mitropoulou, C, Patrinos, GP, Pirmohamed, M, Samwald, M, Schaeffeler, E, Schwab, M, Steinberger, D, Stingl, J, Sunder‐Plassmann, G, Toffoli, G, Turner, RM, van Rhenen, MH, Swen, JJ, Guchelaar, H‐J

“…Despite scientific and clinical advances in the field of pharmacogenomics (PGx), application into routine care remains limited. Opportunely, several…”
Get full text

Pharmacogenetics: From Bench to Byte- An Update of Guidelines by Swen, JJ, Nijenhuis, M, Boer, A, Grandia, L, Maitland‐van der Zee, AH, Mulder, H, Rongen, GAPJM, Schaik, RHN, Schalekamp, T, Touw, DJ, Weide, J, Wilffert, B, Deneer, VHM, Guchelaar, H‐J

“…Currently, there are very few guidelines linking the results of pharmacogenetic tests to specific therapeutic recommendations. Therefore, the Royal Dutch…”
Get full text

Pharmacogenetics: From Bench to Byte by Swen, JJ, Wilting, I, Goede, AL, Grandia, L, Mulder, H, Touw, DJ, Boer, A, Conemans, JMH, Egberts, TCG, Klungel, OH, Koopmans, R, Weide, J, Wilffert, B, Guchelaar, H‐J, Deneer, VHM

“…Despite initial enthusiasm,1,2,3 the use of pharmacogenetics has remained limited to investigation in only a few clinical fields such as oncology and…”
Get full text

Discontinuation of anticoagulant care during admission to a psychiatric hospital by Abdullah-Koolmees, H., Gerbranda, T., Deneer, V. H. M., Tjoeng, M. M., De Ridder, A. J. M., Gardarsdottir, H., Heerdink, E. R.

“…Purpose Continuation of coumarin therapy is important to prevent thromboembolic events. Continuation of medication, unrelated to the reason for hospital…”
Get full text

Factors influencing pharmacists’ clinical decision making in pharmacy practice by Mertens, J.F., Koster, E.S., Deneer, V.H.M., Bouvy, M.L., van Gelder, T.

“…Pharmacists’ clinical decision-making is considered a core process of pharmaceutical care in pharmacy practice, but little is known about the factors…”
Get full text

Cognitive processes in pharmacists' clinical decision-making by Mertens, J F, Kempen, T G H, Koster, E S, Deneer, V H M, Bouvy, M L, van Gelder, T

“…Pharmacists' clinical decision-making is a core process in pharmaceutical care. However, the practical aspects and effective teaching methods of this process…”
Get full text

Maintenance of anesthesia in morbidly obese patients using propofol with continuous BIS-monitoring: a comparison of propofol-remifentanil and propofol-epidural anesthesia by VAN KRALINGEN, S, VAN DE GARDE, E. M. W, VAN DONGEN, E. P. A, DIEPSTRATEN, J, DENEER, V. H. M, VAN RAMSHORST, B, KNIBBE, C. A. J

“…Aim of this study was to evaluate maintenance of anesthesia using propofol with continuous Bispectral Index (BIS)-monitoring in morbidly obese patients…”
Get full text

Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population by van de Garde, E. M. W, Souverein, P. C, van den Bosch, J. M. M, Deneer, V. H. M, Leufkens, H. G. M

“…The aim of the present study was to assess whether the use of angiotensin-converting enzyme (ACE) inhibitors is associated with a decreased risk of…”
Get full text

Combined influence of proton‐pump inhibitors, calcium‐channel blockers and CYP2C192 on on‐treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention by HARMSZE, A. M., VAN WERKUM, J. W., SOUVEREIN, P. C., BREET, N. J., BOUMAN, H. J., HACKENG, C. M., RUVEN, H. J. T., TEN BERG, J. M., KLUNGEL, O. H., DE BOER, A., DENEER, V. H. M.

“…Background: The carriage of CYP2C19*2 and the use of proton‐pump inhibitors (PPIs) and calcium‐channel blockers (CCBs) has been associated with the diminished…”
Get full text

Application of routine electronic health record databases for pharmacogenetic research by Yasmina, A., Deneer, V. H. M., Maitland‐van der Zee, A. H., Staa, T. P., Boer, A., Klungel, O.H.

“…Inter‐individual variability in drug responses is a common problem in pharmacotherapy. Several factors (non‐genetic and genetic) influence drug responses in…”
Get full text

Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation by DENEER, V. H. M, LIE-A-HUEN, L, KINGMA, J. H, PROOST, J. H, GOSSEN, S. A, STUURMAN, A, UYTDEHAAG, G. M. M, DUNSELMAN, P. H. J. M, BROUWERS, J. R. B. J

“…The objectives were to study the absorption kinetics and pharmacodynamics of two oral formulations of flecainide in patients with atrial fibrillation (AF) and…”
Get full text

Variability in on-treatment platelet reactivity explained by CYP2C192 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting by Bouman, Heleen J, Harmsze, Ankie M, van Werkum, Jochem W, Breet, Nicoline J, Bergmeijer, Th O, Ten Cate, Hugo, Hackeng, Christian M, Deneer, Vera H M, Ten Berg, Jurriën M

“…An inadequate response to clopidogrel is mainly attributable to the variable formation of its active metabolite. The CYP2C19*2 loss-of-function polymorphism…”
Get more information

CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium by van der Wouden, CH, Cambon‐Thomsen, A, Cecchin, E, Cheung, KC, Dávila‐Fajardo, CL, Deneer, VH, Dolžan, V, Ingelman‐Sundberg, M, Jönsson, S, Karlsson, MO, Kriek, M, Mitropoulou, C, Patrinos, GP, Pirmohamed, M, Samwald, M, Schaeffeler, E, Schwab, M, Steinberger, D, Stingl, J, Sunder‐Plassmann, G, Toffoli, G, Turner, RM, van Rhenen, MH, Swen, JJ, Guchelaar, H‐J

Get full text

High versus standard clopidogrel loading in patients undergoing carotid artery stenting prior to cardiac surgery to assess the number of microemboli detected with transcranial Doppler: results of the randomized IMPACT trial by Van Der Heyden, J, Van Werkum, J, Hackeng, C M, Kelder, J C, Breet, N J, Deneer, V H M, Ackerstaff, R G A, Tromp, S C, De Vries, J P P M, Vos, J A, Suttorp, M J, Elsenberg, E H A, Van Neerven, D, Schonewille, W J, Wolters, F, Ten Berg, J M

“…The aim of this study was to compare the effects of 300 mg or 600 mg clopidogrel loading dose, prior to carotid artery stenting (CAS) on the number of…”
Get full text

Buccal transport of flecainide and sotalol: effect of a bile salt and ionization state by Deneer, V.H.M, Drese, G.B, Roemelé, P.E.H, Verhoef, J.C, Lie-A-Huen, L, Kingma, J.H, Brouwers, J.R.B.J, Junginger, H.E

“…Patients with infrequent attacks of supraventricular arrhythmia may benefit from self administration of antiarrhythmic drugs on an ‘as required’ basis. The…”
Get full text

Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects by Deneer, V H, Lie-A-Huen, L, Kingma, J H, Proost, J H, Kelder, J C, Brouwers, J R

“…Aims To study the absorption kinetics of sotalol following administration of different formulations. A formulation which results in fast absorption might be…”
Get full text

Inhibition of platelet function by abciximab or high-dose tirofiban in patients with STEMI undergoing primary PCI: a randomised trial by van Werkum, J W, Gerritsen, W B M, Kelder, J C, Hackeng, C M, Ernst, S M, Deneer, V H M, Suttorp, M J, Rensing, B J W M, Plokker, H W M, Ten Berg, J M

“…In patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI, few data exist on the magnitude of platelet activation, aggregation…”
Get full text

Cost-effectiveness of clopidogrel versus ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome by Van Den Broek, W W A, Van Paassen, J G, Gimbel, M E, Deneer, V H M, Ten Berg, J M, Vreman, R A

“…Abstract Background/Introduction In older patients with non-ST-elevation acute coronary syndrome (NSTEMI) the POPular AGE trial clopidogrel showed superiority…”
Get full text

Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis by Brill, Margreke J E, Houwink, Aletta P I, Schmidt, Stephan, Van Dongen, Eric P A, Hazebroek, Eric J, van Ramshorst, Bert, Deneer, Vera H, Mouton, Johan W, Knibbe, Catherijne A J

“…As morbidly obese patients are prone to surgical site infections, adequate blood and subcutaneous tissue concentrations of prophylactic antibiotic agents…”
Get full text

CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD) by Kranendonk, J, Willems, LH, Vijver-Coppen, RJ. van der, Coenen, M., Adang, E., Donders, R., Zeebregts, CJ, Deneer, VHM, Reijnen, MMPJ, Kramers, C, Warlé, MC

“…Clopidogrel is recommended in international guidelines to prevent arterial thrombotic events in patients with peripheral arterial disease (PAD). Clopidogrel…”
Get full text